ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Trial Assesses Shorter Moxifloxacin Therapy

by Sue Pondrom • May 2, 2010

  • Tweet
  • Email
Print-Friendly Version

What is the efficacy and safety of a five-day moxifloxacin regimen in the treatment of acute bacterial rhinosinusitis (ABRS)?

You Might Also Like

  • Intranasal Corticosteroid Not Recommended as Monotherapy for Acute Rhinosinusitis
  • Nonclinical Factors Influence Antibiotic Overuse in Acute Sinusitis
  • Shorter Height Associated with Higher Risk of Posterior Glottic Stenosis
  • Temporary Trial May Improve Compliance with CPAP
Explore This Issue
May 2010

Background: There is a lack of clarity regarding the role of antimicrobials in ABRS treatment. Although current guidelines encourage the use of antimicrobials, it is difficult to identify appropriate patients. Additionally, there would be benefits to reducing treatment duration, including lower drug exposure, greater compliance and minimized potential for resistance.

Study Design: A prospective, randomized, multicenter, 2:1 double-blind, phase IIIb clinical trial

Setting: Thirty-seven centers (ear, nose and throat practices; family practitioners; and general medical clinics) in the U.S.

Synopsis: Microbiologic assessment was provided at enrollment for 374 patients with ABRS who were given 400 mg of oral moxifloxacin or a matching placebo daily for five days. The primary end point was clinical response with secondary efficacy variables, including patient-reported symptom improvement. Although moxifloxacin did not show clinical superiority to placebo in the modified intent-to-treat (mITT) population, it did reduce the rate of clinical failure by 42.3 percent compared with placebo, and symptom duration was shorter in moxifloxacin-treated patients, who experienced greater and faster improvements overall. However, the authors said the study may have been affected by confounding factors. For example, the study was not sufficiently powered to detect a difference from placebo with a greater than estimated success rate, patients with nonbacterial sinusitis may have been included, the high use of concomitant medications in the placebo arm may have masked continuing sinusitis symptoms, the use of a sinus tap may have had an adjunctive effect on bacterial clearance and, because an arbitrary point for analysis is problematic, the test-of-cure visit may have been too early.

Bottom Line: Although five-day moxifloxacin did not show clinical superiority to placebo, researchers noted positive trends favoring moxifloxacin when assessing secondary efficacy variables, such as symptom relief. Patients on moxifloxacin also used fewer concomitant medicines.

Citation: Hadley JA, Mösges R, Desrosiers M, et al. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. Laryngoscope. 2010;120(5):1057-1062.

—Reviewed by Sue Pondrom

Filed Under: Literature Reviews, Rhinology Tagged With: ABRS, acute bacterial rhinosinusitis, moxifloxacin regimen, rhinologyIssue: May 2010

You Might Also Like:

  • Intranasal Corticosteroid Not Recommended as Monotherapy for Acute Rhinosinusitis
  • Nonclinical Factors Influence Antibiotic Overuse in Acute Sinusitis
  • Shorter Height Associated with Higher Risk of Posterior Glottic Stenosis
  • Temporary Trial May Improve Compliance with CPAP

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Why Virtual Grand Rounds May Be Here to Stay
    • Otolaryngologist Leverages His Love of Pinball into Second Business
    • These New Imaging Advances May Help to Protect Parathyroids
    • Is the Training and Cost of a Fellowship Worth It? Here’s What Otolaryngologists Say
    • Which Otologic Procedures Poses the Greatest Risk of Aerosol Generation?

Polls

Have you used 3D-printed materials in your otolaryngology practice?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.